Mistakes in ... 2021 - 46

ueg education
Mistakes in... 2021
64. Davis JPE and Caldwell SH. Healing gone wrong:
convergence of hemostatic pathways and liver
fibrosis? Clin Sci (Lond) 2020; 134: 2189-2201.
65. Giannini EG, Stravitz RT and Caldwell SH. Portal vein
thrombosis and chronic liver disease progression:
The closer you look the more you see. Hepatology
2016; 63: 342-343.
66. Luca A, Caruso S, Milazzo M, et al. Natural course of
extrahepatic nonmalignant partial portal vein
thrombosis in patients with cirrhosis. Radiology 2012;
265: 124-132.
67. Nery F, Chevret S, Condat B, et al. Causes and
consequences of portal vein thrombosis in 1,243
patients with cirrhosis: results of a longitudinal study.
Hepatology 2015; 61: 660-667.
68. Intagliata NM, Henry ZH, Maitland H, et al. Direct oral
anticoagulants in cirrhosis patients pose similar risks
of bleeding when compared to traditional
anticoagulation. Dig Dis Sci 2016; 61: 1721-1727.
69. Naymagon L, Tremblay D, Zubizarreta N, et al. The
efficacy and safety of direct oral anticoagulants in
noncirrhotic portal vein thrombosis. Blood Adv 2020;
4: 655-666.
70. Rodriguez-Castro KI, Vitale A, Fadin M, et at. A
prediction model for successful anticoagulation in
cirrhotic portal vein thrombosis. Eur J Gastroenterol
Hepatol 2019; 31: 34-42.
71. Giannini EG and Savarino V. Which anticoagulant
drug should be used to treat portal vein thrombosis
in patients with chronic liver disease? Clin
Gastroenterol Hepatol 2013; 11: 103.
72. Pisters R, Lane DA, Nieuwlaat R, et al. A novel userfriendly
score (HAS-BLED) to assess 1-year risk of
major bleeding in patients with atrial fibrillation: The
Euro Heart Survey. Chest 2010; 138: 1093-1100.
73. Zhang S, Meng H, Chen Q, et al. Is frailty a prognostic
factor for adverse outcomes in older patients with
acute coronary syndrome? Aging Clin Exp Res 2020;
32: 1435-1442.
74. Olson ST, Richard B, Izaguirre G, et al. Molecular
mechanisms of antithrombin-heparin regulation of
blood clotting proteinases. A paradigm for
understanding proteinase regulation by serpin family
protein proteinase inhibitors. Biochimie 2010;
92: 1587-1596.
75. Bechmann LP, Sichau M, Wichert M, et al. Lowmolecular-weight
heparin in patients with advanced
cirrhosis. Liver Int 2011; 31: 75-82.
76. Goodpasture EW. Fibrinolysis in chronic hepatic
insufficiency. Bull Johns Hopkins Hosp 1914;
25: 330-336.
77. Joist JH. AICF and DIC in liver cirrhosis: expressions of
a hypercoagulable state. Am J Gastroenterol 1999;
94: 2801-2803.
78. Rijken DC, Kock EL, Guimarães AH, et al. Evidence for
an enhanced fibrinolytic capacity in cirrhosis as
measured with two different global fibrinolysis tests.
J Thromb Haemost 2012; 10: 2116-2222.
79. de Franchis R, on behalf of the Baveno VI Faculty.
Expanding consensus in portal hypertension: Report
of the Baveno VI Consensus Workshop: Stratifying
risk and individualizing care for portal hypertension.
J Hepatol 2015; 63: 743-752.
80. Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal
hypertensive bleeding in cirrhosis: Risk stratification,
diagnosis, and management: 2016 practice guidance
by the American Association for the study of liver
diseases. Hepatology 2017; 65: 310-335.
81. DeAngelis GA, Khot R, Haskal ZJ, et al. Bleeding risk
and management in interventional procedures in
chronic liver disease. J Vasc Interv Radiol 2016; 27:
1665-1674.
82. Ben-Ari Z, Panagou M, Patch D, et al.
Hypercoagulability in patients with primary biliary
cirrhosis and primary sclerosing cholangitis
evaluated by thrombelastography. J Hepatol 1997;
26: 554-559.
83. Montalto P, Vlachogiannakos J, Cox DJ, et al. Bacterial
infection in cirrhosis impairs coagulation by a heparin
effect: a prospective study. J Hepatol 2002;
37: 463-470.
Your coagulation in liver disease briefing
UEG Week
* 'Complications of liver cirrhosis' session at UEG Week
2019 [https://ueg.eu/library/session/
complications-of-liver-cirrhosis/156/2146].
* 'Hepatology from bench to bedside' session at UEG Week
2019 [https://ueg.eu/library/session/
hepatology-from-bench-to-bedside/156/2557].
* 'Crash course: When the liver starts talking' session
at UEG Week 2018 [https://ueg.eu/library/session/
crash-course-when-the-liver-starts-talking
/153/2040].
* 'Advances in the management of cirrhosis' session at
UEG Week 2018 [https://ueg.eu/library/session/
advances-in-the-management-of-cirrhosis/153/2070].
* 'Complications of liver cirrhosis' session at UEG Week
2015 [https://ueg.eu/library/session/
complications-of-liver-cirrhosis/109/1372].
Standards and Guidelines
* EASL. EASL Standards and Guidelines: Vascular diseases
of the liver. J Hepatol 2016: 64; 179-202
[https://ueg.eu/library/easl-standards-and-guidelinesvascular-diseases-of-the-liver/125496].
*
De Franchis R, on behalf of the Baveno VI Faculty.
Expanding consensus in portal hypertension: Report of
the Baveno VI Consensus Workshop: Stratifying risk and
individualizing care for portal hypertension. J Hepatol
2015: 63; 743-752 [https://ueg.eu/library/
expanding-consensus-in-portal-hypertension-report-ofthe-baveno-vi-consensus-workshop-stratifying-risk-andindividualizing-care-for-portal-hypertension/144414].
*
NICE guideline NG50. Cirrhosis in over 16s: assessment
and management. July 2016
[https://ueg.eu/library/cirrhosis-in-over-16s-assessment
-and-management/141801].
34

Mistakes in ... 2021

Table of Contents for the Digital Edition of Mistakes in ... 2021